Alercell Unveils AI Cancer Detection Platform Validated on 199,000+ Patient Records

News Provided By

Alercell, Inc.

March 23, 2026, 13:30 GMT

Share This Article

LENA Platform's four LDT products detect leukemia up to 41 months before symptoms — now live at alercell.com

Alercell is proving that rigorous epigenetic science and AI validation make early detection both clinically superior and commercially compelling.”

— Dr. Frederic Scheer, PhD

BOZEMAN, MT, UNITED STATES, March 23, 2026 /EINPresswire.com/ --AlercellInc., a precision oncology biotechnology company, today announced the official launch of alercell.com, its fully redesigned digital platform giving the medical community, clinical partners, andinvestorscomprehensive access to the company's proprietary LENA epigenetic diagnostic suite. Simultaneously, Alercell announced the opening of its Series A fundraising round to accelerate FDA submission, clinical expansion, and international commercialization of the LENA Platform.

Read more here: https://www.einpresswire.com/article/901090411/alercell-unveils-ai-cancer-detection-platform-validated-on-199-000-patient-records